This slide shows the results from the primary efficacy
endpoint, which was the venogram performed on day 6. The results are
expressed as a percent of interpretable venograms at the end of the
hospitalization period. Approximately 81-82% of patients assigned
to each treatment group had interpretable venograms.
Dalteparin begun either pre-op or post-op significantly
reduced the incidence of total DVT (thigh and calf) compared to warfarin.
More importantly, Dalteparin significantly reduced the incidence of
proximal DVT (knee and above) compared to warfarin. This benefit was
achieved at some cost in the group given dalteparin pre-op because
their rate of major bleeding doubled compared to warfarin (8.9% vs.
4.5%). Most of these bleeding complications occurred at the surgical
site. There was no statistically significant difference in major bleeding
between the groups given post-op dalteparin or warfarin.
